Utility of blood procalcitonin concentration in the management of cancer patients with infections

被引:34
|
作者
Durnas, Bonita [1 ,2 ]
Watek, Marzena [1 ]
Wollny, Tomasz [1 ]
Niemirowicz, Katarzyna [3 ]
Marzec, Michal [4 ]
Bucki, Robert [2 ,3 ]
Gozdz, Stanislaw [1 ]
机构
[1] Holy Cross Oncol Ctr Kielce, Kielce, Poland
[2] Jan Kochanowski Univ Kielce, Dept Physiol Pathophysiol & Microbiol Infect, Fac Hlth Sci, Kielce, Poland
[3] Med Univ Bialystok, Dept Microbiol & Nanobiomed Engn, Mickiewicza 2c, PL-15222 Bialystok, Poland
[4] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA
来源
ONCOTARGETS AND THERAPY | 2016年 / 9卷
关键词
procalcitonin; cancer; infection; C-REACTIVE PROTEIN; CRITICALLY-ILL PATIENTS; SERUM PROCALCITONIN; BACTERIAL-INFECTION; MARKER; BACTEREMIA; BIOMARKER; SEPSIS; PARAMETERS; CALCITONIN;
D O I
10.2147/OTT.S95600
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Diagnosis of infections in cancer patients is usually problematic since differentiating between infection and fever of unknown origin is often a considerable clinical challenge. In general, increase concentration of blood procalcitonin (PCT) is associated with severe bacterial infection. PCT with an optimal cutoff level of 0.5 ng/mL seems to be the most helpful biochemical parameter in detecting severe infections, mainly bloodstream infection, in patients with hematological cancers. In all clinical situations, the elevated level of PCT should be carefully analyzed, always with a thorough physical examination and an appropriate microbiological assessment.
引用
收藏
页码:469 / 475
页数:7
相关论文
共 50 条
  • [31] Utility of serum procalcitonin determination as an early marker of invasive bacterial infections in children
    Cattozzo, Giampaolo
    Graziani, Daniela
    Nespoli, Luigi
    De Luca, Giancarlo
    BIOCHIMICA CLINICA, 2007, 31 (06) : 558 - 561
  • [32] Diagnostic and Therapeutic Utility of Procalcitonin in Various Infections: A Tertiary Care Center Experience
    Siddique, Ayesha
    Aslanzadeh, Jaber
    Orelup, Eric
    Makowski, Gregory
    LABORATORY INVESTIGATION, 2019, 99
  • [33] Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations
    Schuettrumpf, Silke
    Binder, Lutz
    Hagemann, Thorsten
    Berkovic, Dinko
    Truemper, Lorenz
    Binder, Claudia
    CLINICAL INFECTIOUS DISEASES, 2006, 43 (04) : 468 - 473
  • [34] Procalcitonin in patients with colorectal cancer
    Keramidaris, D.
    Koronakis, N.
    Lagoudianakis, E. E.
    Pappas, A.
    Koukoutsis, I.
    Chrysikos, I.
    Karavitis, G.
    Toutouzas, K.
    Manouras, A.
    JOURNAL OF BUON, 2013, 18 (03): : 623 - 628
  • [35] Alexin concentration in cancer patients' blood.
    Engel, CS
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1910, 36 : 986 - 986
  • [36] Management of patients with respiratory infections in primary care: procalcitonin, C-reactive protein or both?
    Meili, Marc
    Mueller, Beat
    Kulkarni, Prasad
    Schuetz, Philipp
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (05) : 587 - 601
  • [37] MANAGEMENT OF INFECTIONS IN IMMUNOCOMPROMISED CANCER-PATIENTS
    BAJETTA, E
    GASPARINI, G
    MONFARDINI, S
    VOLONTERIO, A
    BUZZONI, R
    SHINDE, S
    HAEMATOLOGICA, 1984, 69 (05) : 576 - 597
  • [38] NATURE AND MANAGEMENT OF INFECTIONS IN PATIENTS WITH ADVANCED CANCER
    ROLSTON, KVI
    BODEY, GP
    TEXAS MEDICINE, 1986, 82 (05) : 44 - 48
  • [39] Prevention and management of oral infections in cancer patients
    Heimdahl, A
    SUPPORTIVE CARE IN CANCER, 1999, 7 (04) : 224 - 228
  • [40] Management of viral infections in immunocompromised cancer patients
    Reusser, PE
    SWISS MEDICAL WEEKLY, 2002, 132 (27-28) : 374 - 378